



ASPIRA PATHLAB AND DIAGNOSTICS LIMITED

MEDIA RELEASE

We are pleased to announce that Aspira Pathlab & Diagnostics Limited (“**Company**”), engaged in the business of running, owning, managing and administering Diagnostics Centers, has been admitted to trade in the BSE under direct listing.

The equity shares of the Company (Scrip Code: 540788) are listed and admitted to dealings on the BSE under the security ID “**ASPIRA**” in the list of 'XT' Group series with effect from December 05, 2017 vide the notice no 20171201-20 dated December 01, 2017.

It is a matter of pride for the Company to get its equity shares listed on the BSE that has nationwide trading terminal and is known to as Asia’s first and fastest stock exchange. The listing on the BSE will benefit the Company by enabling it to add more liquidity and marketability of its securities on continuous basis, creating and building its image, deepening its corporate governance practices and helping it to raise capital by attracting a wide and varied body of institutional and professional investors.

It is indeed a proud moment for all the founders, investors, employees, business partners and other stakeholders of Company.